pharmaphorum

FEBRUARY 19, 2021

Ashfield Advisory , part of UDG Healthcare plc, today announced the acquisition of PHMR Limited, a Market Access Consultancy and specialist in Health Economics and Outcomes Research (HEOR). The post UDG Healthcare acquires market access, HEOR specialist, PHMR Limited as Ashfield Advisory appeared first on.

Marketing 52

Marketing Scientist Research 52

pharmaphorum

APRIL 12, 2021

UK comms agency Fishawack Health has acquired the health economics outcomes research (HEOR) consultancy PRMA Consulting. The company said that the acquisition will allow it to offer a HEOR consultancy service that spans the globe.

Marketing 52

Marketing Production Development Research 52

Cloudbyz

JUNE 7, 2023

Health Economics and Outcomes Research (HEOR) RWE is instrumental in Health Economics and Outcomes Research (HEOR), offering insights into the economic impact, including cost-effectiveness, and patient-reported outcomes of medical devices.

Clinical Trials 89

Clinical Trials Clinical Trials Trials Marketing 89

pharmaphorum

NOVEMBER 22, 2020

Formed in 2011 by David Rowley and chief operating officer Sandy Royden, OPEN Health has pursued several M&A deals over the years, with the most recent including a merger with med comms provider Peloton in 2018 – following OPEN’s acquisition with Amulet Capital Partners – and one last year with HEOR and market access firm Pharmerit.

Marketing 79

Marketing Sales 79

pharmaphorum

DECEMBER 6, 2022

Work should also be undertaken on making product studies generalisable between national jurisdictions, the design of real-world evidence (RWE), healthcare evaluation outcomes research (HEOR) and clinical workflow pilot studies, and how DTx can be adapted for different languages and cultures.

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Drug Channels

AUGUST 22, 2022

Reimbursement Strategies and Contracting Value-Based Contracting Frameworks and Considerations HEOR, RWE and Their Roles in Reimbursement Rebates and Reimbursement—Breaking Down the Pricing Strategy And more! Exclusive Offer: View the agenda and register today.

Compliance 56

Compliance Drugs Branding Production 56

pharmaphorum

AUGUST 17, 2021

AXON is expecting to make several appointments in the US in the coming months to support existing clients and potential new opportunities, as we expand our work in medical affairs, clinical trial services, HEOR and real-world evidence, and public relations.

Clinical Trials 98

Clinical Trials Clinical Trials Branding Marketing 98

Clinical Trial Podcast

FEBRUARY 23, 2021

Health Economics and Outcomes Research (HEOR). This is where HEOR comes into play. This is where HEOR comes into play. A HEOR team helps create a body of evidence that the new drug or device has health benefits such as improved quality of life. HEOR has an in-depth understanding of country-specific requirements.

Clinical Research 105

Clinical Research Research Clinical Trials Clinical Trials 105

pharmaphorum

MARCH 30, 2021

So HEOR and market access must be involved up front, but she advocates a wider collaborative approach which also includes external perspectives from payers, policy makers and influential groups such as ISPOR. We had a lot of different perspectives from people in HEOR, market access, regulatory and marketing.

Marketing 80

Marketing Trials Regulation Production 80

pharmaphorum

JUNE 8, 2022

Combining our skills and experiences across HEOR, market access, and policy will allow us to partner with clients to provide a deeper set of integrated capabilities not offered by other firms,” says David Sykes, President of Policy, Access, Value, and Evidence at FH. . We are delighted to welcome the Avalere team to FH.

Marketing 52

Marketing Life Science Production Regulation 52

XTalks

NOVEMBER 22, 2021

AppliedVR says it will continue testing the VR system to demonstrate both its clinical efficacy and cost-effectiveness to treat pain — for the latter, it plans to complete multiple health economics and outcomes (HEOR) studies with commercial payers.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Trials 52

pharmaphorum

DECEMBER 15, 2022

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim’s Ofev, following new guidance from health technology assessment agency NICE.

Doctors 105

Doctors Doctor Clinical Trials Clinical Trials 105

pharmaphorum

NOVEMBER 16, 2022

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid, Roche’s RoActemra and Eli Lilly’s Olumiant – but turned down another five in draft guidance published this week.

Drugs 104

Drugs Vaccination Vaccine Antibody 104

pharmaphorum

SEPTEMBER 6, 2022

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.

Hormones 110

Hormones Drugs Manufacturing Research 110

pharmaphorum

JUNE 20, 2022

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli Lilly’s Verzenios, after new guidance from NICE backed use of the drug after surgery for early-stage tumours.

Hormones 115

Hormones Medicine Drugs Production 115

pharmaphorum

SEPTEMBER 22, 2022

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL).

Medicine 98

Medicine Drugs Marketing Production 98

pharmaphorum

JULY 14, 2022

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – in England. .

Drugs 104

Drugs Hormones Genome Genomics 104

pharmaphorum

NOVEMBER 25, 2022

The European Commission has provided around €7 million ($7.2 million) in funding to a new project that aims to boost the ability of hospitals within the EU to collect real-world data (RWD) to gauge the effectiveness of novel cancer therapies.

Regulation 90

Regulation Medicine Development Drugs 90

pharmaphorum

AUGUST 19, 2021

Novartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a green light from NICE.

Clinical Trials 124

Clinical Trials Clinical Trials Licensing Licensing 124

pharmaphorum

JULY 15, 2022

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high cardiovascular risk because of raised triglyceride levels. mmol/litre or above) in their blood who are already taking statins.

Production 98

Production Marketing Drugs Medicine 98

pharmaphorum

FEBRUARY 8, 2022

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label.

Drugs 105

Drugs Contract Manufacturing Clinical Trials Clinical Trials 105

pharmaphorum

DECEMBER 22, 2022

One of the most highly-anticipated developments in pharma next year will be the FDA’s verdict on Eisai’s accelerated application for lecanemab in Alzheimer’s disease, due early in January.

Antibody 77

Antibody Trials Drugs Marketing 77

pharmaphorum

DECEMBER 17, 2021

After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been approved for routine NHS use after surgery for people with melanoma to prevent the cancer returning.

Regulation 98

Regulation Trials Drugs Development 98

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry.

Drugs 98

Drugs Medicine Clinical Trials Clinical Trials 98

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. .

Sales 110

Sales Medicine Drugs Marketing 110

pharmaphorum

OCTOBER 21, 2021

UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Wales for the rare disease acute hepatic porphyria (AHP), after its advisors issued a positive verdict on the drug.

Gene Silencing 98

Gene Silencing Gene RNA Drugs 98

pharmaphorum

JULY 9, 2021

Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use by NICE in draft guidance.

Gene Therapy 105

Gene Therapy Gene In-Vivo Marketing 105

pharmaphorum

SEPTEMBER 1, 2021

Novartis’ cholesterol-lowering drug Leqvio will be made available on the NHS in England and Wales, and could help to prevent up to 30,000 deaths, according to NICE.

Drugs 98

Drugs Trials Gene Silencing Genetics 98

pharmaphorum

NOVEMBER 5, 2021

Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca’s SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft recommendations.

Drugs 91

Drugs Trials Marketing Medicine 91

pharmaphorum

JUNE 30, 2021

bluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced in the UK earlier this year to speed up NHS access to promising new medicines.

Gene Therapy 98

Gene Therapy Gene Medicine Life Science 98

pharmaphorum

DECEMBER 21, 2022

AstraZeneca and Daiichi Sankyo’s Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available via the Cancer Drugs Fund.

Drugs 63

Drugs Clinical Trials Clinical Trials Antibody 63

pharmaphorum

MARCH 8, 2021

NHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they have BRCA-positive advance prostate cancer, according to draft guidance from NICE.

Hormones 98

Hormones Marketing Trials DNA 98

pharmaphorum

NOVEMBER 7, 2022

Draft guidance in the UK has provisionally recommended that digital cognitive behavioural therapy (CBT) apps can be used within the NHS to treat children and young people with mild to moderate anxiety.

Containment 63

Containment Research Marketing 63

pharmaphorum

JANUARY 19, 2021

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

Medicine 98

Medicine Gene Drugs Production 98

pharmaphorum

MARCH 9, 2022

There isn’t enough evidence to support the use of Merck & Co/MSD’s Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, according to the UK cost effectiveness watchdog NICE.

Drugs 74

Drugs Marketing 74

pharmaphorum

JANUARY 19, 2023

Alnylam’s gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available on the NHS in England and Wales.

Gene Silencing 52

Gene Silencing RNA Production Protein 52

pharmaphorum

JANUARY 13, 2023

Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.

Doctors 52

Doctors Doctor Drugs Medicine 52